Bartolome Burguera
Overview
Explore the profile of Bartolome Burguera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1222
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nachawi N, Griebeler M, Xiao H, Bena J, Pantalone K, Burguera B
Obes Res Clin Pract
. 2025 Mar;
PMID: 40032542
Background: A pragmatic randomized controlled trial (RCT) reported superior weight loss when anti-obesity medications (AOMs) were added to a 1-year employer-based weight management program (WMP+Rx) compared to WMP alone. Evidence...
2.
Kushner R, Ryan D, Deanfield J, Kokkinos A, Cercato C, Wilding J, et al.
Obesity (Silver Spring)
. 2025 Feb;
33(3):452-462.
PMID: 39948761
Objective: The objective of this study was to assess safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo, beyond reduction in major adverse cardiovascular events, in patients with established cardiovascular...
3.
Rodriguez P, Breslaw N, Xiao H, Bena J, Jenkins K, Isaacs D, et al.
Diabetes Obes Metab
. 2024 Nov;
27(2):642-651.
PMID: 39532398
Aims: The study aims to examine the outcome of replacement of prandial insulin with once-weekly subcutaneous semaglutide in people with type 2 diabetes reasonably controlled on multiple daily insulin injections...
4.
Burguera B, Griebeler M, Garvey W
Cleve Clin J Med
. 2024 Nov;
91(11):671-676.
PMID: 39486846
No abstract available.
5.
Sharma A, Mariam A, Zacherle E, Milinovich A, Bauman J, Sugano D, et al.
Diabetes Obes Metab
. 2024 Aug;
26(11):5347-5357.
PMID: 39192531
Aims: To investigate the independent contributions of glycated haemoglobin (HbA1c) reduction and weight loss to clinical outcomes in patients with type 2 diabetes (T2D) treated with antidiabetic drugs, including glucagon-like...
6.
Lomeli L, Makin V, Bartholomew J, Burguera B
Cleve Clin J Med
. 2024 Jul;
91(7):425-436.
PMID: 38950986
Lymphedema and lipedema are chronic debilitating disorders that most commonly affect the upper and lower extremities. Although they can appear similar, they differ in important ways, which the authors of...
7.
Kahn S, Deanfield J, Jeppesen O, Emerson S, Boesgaard T, Colhoun H, et al.
Diabetes Care
. 2024 Jun;
47(8):1350-1359.
PMID: 38907683
Objective: To determine whether semaglutide slows progression of glycemia in people with cardiovascular disease and overweight or obesity but without diabetes. Research Design And Methods: In a multicenter, double-blind trial,...
8.
Ryan D, Lingvay I, Deanfield J, Kahn S, Barros E, Burguera B, et al.
Nat Med
. 2024 May;
30(7):2049-2057.
PMID: 38740993
In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes. Here in...
9.
Pantalone K, Rogen B, Zirm P, Xiao H, Bena J, Barnard G, et al.
Diabetes Ther
. 2024 Apr;
15(5):1201-1214.
PMID: 38573466
Introduction: This study aimed to compare weight loss and glycated hemoglobin (HbA)-reduction effects of two obesity-centric, weight-loss management approaches (with or without anti-obesity medication) versus usual glucose-centric care in patients...
10.
Hoying D, Miller K, Tanzo J, Kim J, Bena J, Burguera B, et al.
Otolaryngol Head Neck Surg
. 2023 Dec;
170(3):708-723.
PMID: 38108590
Objective: The aim of this Meta-analysis and systematic review was to perform a comprehensive assessment of the association of chronic rhinosinusitis (CRS) with overweight/obesity, leptin hormone, and its associated metabolic...